Roche Holding AG Diagnostics Investor Day (Virtual) Transcript - Thomson StreetEvents

Roche Holding AG Diagnostics Investor Day (Virtual) Transcript

Roche Holding AG Diagnostics Investor Day (Virtual) Transcript - Thomson StreetEvents
Roche Holding AG Diagnostics Investor Day (Virtual) Transcript
Published Mar 23, 2021
Published Mar 23, 2021
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of ROG.S corporate analyst meeting

  
Report Type:

Transcript

Source:
Thomson StreetEvents
Company:
Roche Holding AG
Ticker
ROG.S
Time
1:00pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Scott Bardo - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : One question to Michael, please. Thank you very much for taking us through the infectious disease portfolio. It seems now that Roche has a strong offering in both low-plex testing for molecular diagnostic, multiplexing for decentralized settings with GenMark and now you comment on multiplexing in a more high-volume setup. Can you give us some sense as to how you think the market for multianalyte PCR testing is going to shake out between these various different buckets of low-plex, decentralized and high volume? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. MARCH 23, 2021 / 1:00PM, ROG.S - Roche Holding AG Diagnostics Investor Day (Virtual) And second quick question, please, if possible, for Benjamin. Thanks for showing us the integrated immunoassay clinical chemistry analyzer. Can you help us understand whether Roche has particular market strengths in one of these modalities? You're strong in immunoassay or clinical chemistry? How can you use this combined solution to increase your positioning? And last question, if I can, Birgit, to Thomas. There's been a lot of focus on the molecular diagnostic PCR testing for COVID and the pricing environment that may unfold. Thomas, can you share any thoughts as to pricing for molecular diagnostics for the post-pandemic portfolio? Do you think levels would be now sustainably higher given government activity here? Or could there be indeed more longer-term pressure due to a rapid entrance of multiple players?

Table Of Contents

Roche Holding AG Pharma Day (Virtual) Transcript – 2021-09-14 – US$ 54.00 – Edited Transcript of ROG.S corporate analyst meeting</ 14-Sep-21 12:00pm GMT

Half Year 2021 Roche Holding AG Earnings Presentation Transcript – 2021-07-22 – US$ 54.00 – Edited Transcript of ROG.S earnings conference call or presentation 22-Jul-21 12:00pm GMT

Roche Holding AG Virtual Event on Key Evrysdi Data Presented at 2021 CureSMA Annual Meeting Transcript – 2021-06-14 – US$ 54.00 – Edited Transcript of ROG.S corporate analyst meeting</ 14-Jun-21 2:00pm GMT

Roche Holding AG Virtual Event on Key Oncology Data Presented at 2021 ASCO Annual Meeting Transcript – 2021-06-08 – US$ 54.00 – Edited Transcript of ROG.S corporate analyst meeting</ 8-Jun-21 2:00pm GMT

Q1 2021 Roche Holding AG Corporate Sales Call Transcript – 2021-04-21 – US$ 54.00 – Edited Transcript of ROG.S sales update conference call or presentation 21-Apr-21 12:00pm GMT

Roche Holding AG Virtual Event on Key Data Presented at the 2021 MDA Virtual Clinical & Scientific Conference Transcript – 2021-03-19 – US$ 54.00 – Edited Transcript of ROG.S corporate analyst meeting</ 19-Mar-21 1:00pm GMT

Roche Holding AG Virtual Event on Key Ophthalmology Data Presented at the Angiogenesis 2021 Meeting Transcript – 2021-02-16 – US$ 54.00 – Edited Transcript of ROG.S corporate analyst meeting</ 16-Feb-21 3:30pm GMT

Full Year 2020 Roche Holding AG Earnings Presentation Transcript – 2021-02-04 – US$ 54.00 – Edited Transcript of ROG.S earnings conference call or presentation 4-Feb-21 1:00pm GMT

Roche Holding AG Virtual Event on Key Hematology Data Presented at ASH 2020 Transcript – 2020-12-08 – US$ 54.00 – Edited Transcript of ROG.S corporate analyst meeting</ 8-Dec-20 3:00pm GMT

Q3 2020 Roche Holding AG Corporate Sales Call Transcript – 2020-10-15 – US$ 54.00 – Edited Transcript of ROG.S sales update conference call or presentation 15-Oct-20 12:00pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Roche Holding AG Diagnostics Investor Day (Virtual) Transcript" Mar 23, 2021. Alacra Store. Nov 06, 2026. <http://www.alacrastore.com/thomson-streetevents-transcripts/Roche-Holding-AG-Diagnostics-Investor-Day-Virtual-T13583927>
  
APA:
Thomson StreetEvents. (2021). Roche Holding AG Diagnostics Investor Day (Virtual) Transcript Mar 23, 2021. New York, NY: Alacra Store. Retrieved Nov 06, 2026 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Roche-Holding-AG-Diagnostics-Investor-Day-Virtual-T13583927>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.